In the Senate of the United States, 
December 11, 2020. 
Resolved, That the bill from the House of Representa-
tives (H.R. 4764) entitled ‘‘An Act to reauthorize the Stem 
Cell Therapeutic and Research Act of 2005, and for other 
purposes.’’, do pass with the following 
AMENDMENT: 
Strike all after the enacting clause and insert the 
following: 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Timely ReAuthorization 
of Necessary Stem-cell Programs Lends Access to Needed 
Therapies Act of 2020’’ or the ‘‘TRANSPLANT Act of 
2020’’. 
SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL 
TRANSPLANTATION PROGRAM. 
(a) ADVISORY COUNCIL MEETINGS.—Subsection (a) of 
section 379 of the Public Health Service Act (42 U.S.C.
† HR 4764 EAS 
274k) is amended by adding at the end the following new 
paragraph: 
‘‘(7) The Secretary shall convene the Advisory 
Council at least two times each calendar year.’’. 
(b) INCREASING COLLECTION.— 
(1) TECHNICAL CLARIFICATION.—Effective as if 
included in the enactment of Public Law 114–104 
(the Stem Cell Therapeutic and Research Reauthor-
ization Act of 2015), the amendment to section 
379(d)(2)(B) of the Public Health Service Act (42 
U.S.C. 274k(d)(2)(B)) in section 2(a)(2) of Public 
Law 114–104 is amended by inserting ‘‘goal of in-
creasing collections of high quality’’ before ‘‘cord blood 
units,’’. 
(2) ELIMINATING
DEADWOOD.—Subparagraph 
(B) of section 379(d)(2) of the Public Health Service 
Act (42 U.S.C. 274k(d)(2)) is amended by striking the 
second and third sentences in such subparagraph. 
(c) PERIODIC REVIEW OF STATE OF SCIENCE.—Sec-
tion 379 of the Public Health Service Act (42 U.S.C. 274k) 
is amended by adding at the end the following new sub-
section: 
‘‘(o) PERIODIC REVIEW OF STATE OF SCIENCE.— 
‘‘(1) REVIEW.—Not less than every two years, 
the Secretary, in consultation with the Director of the
† HR 4764 EAS 
National Institutes of Health, the Commissioner of 
Food and Drugs, the Administrator of the Health Re-
sources and Services Administration, the Advisory 
Council, and other stakeholders, where appropriate 
given relevant expertise, shall conduct a review of the 
state of the science of using adult stem cells and birth-
ing tissues to develop new types of therapies for pa-
tients, for the purpose of considering the potential in-
clusion of such new types of therapies in the Program. 
‘‘(2) RECOMMENDATIONS.—Not later than June 
30, 2024, the Secretary shall— 
‘‘(A) complete the second review required by 
paragraph (1); and 
‘‘(B) informed by such review, submit to the 
Committee on Health, Education, Labor, and 
Pensions of the Senate and the Committee on 
Energy and Commerce of the House of Rep-
resentatives recommendations on the appro-
priateness of the inclusion of new types of thera-
pies in the Program.’’. 
(d) AUTHORIZATION
OF APPROPRIATIONS.—Section 
379B of the Public Health Service Act (42 U.S.C. 274m) 
is amended by striking ‘‘$33,000,000 for fiscal year 2015 
and $30,000,000 for each of fiscal years 2016 through 2020’’
† HR 4764 EAS 
and inserting ‘‘$30,000,000 for each of fiscal years 2021 
through 2025’’. 
SEC. 3. CORD BLOOD INVENTORY. 
Subsection (g) of section 2 of the Stem Cell Therapeutic 
and Research Act of 2005 (42 U.S.C. 274k note) is amended 
to read as follows: 
‘‘(g) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there is authorized to be appropriated 
$23,000,000 for each of fiscal years 2021 through 2025.’’. 
SEC. 4. ADVANCING THE FIELD OF REGENERATIVE MEDI-
CINE. 
Section 402 of the Public Health Service Act (42 
U.S.C. 282) is amended by adding at the end the following: 
‘‘(o) REGENERATIVE MEDICINE.—The Director of NIH 
shall, as appropriate, continue to consult with the directors 
of relevant institutes and centers of the National Institutes 
of Health, other relevant experts from such institutes and 
centers, and relevant experts within the Food and Drug Ad-
ministration, to further the field of regenerative medicine 
using adult stem cells, including autologous stem cells, 
therapeutic tissue engineering products, human cell and tis-
sue products, human gene therapies, and genetically modi-
fied cells.’’.
† HR 4764 EAS 
SEC. 5. GAO REPORT ON REGENERATIVE MEDICINE WORK-
FORCE. 
Not later than 2 years after the date of enactment of 
this Act, the Comptroller General of the United States shall 
submit to the Committee on Health, Education, Labor, and 
Pensions of the Senate and the Committee on Energy and 
Commerce of the House of Representatives a report that as-
sesses a specialized health care workforce in the field of re-
generative medicine. The report shall include— 
(1) an overview of the current employment levels, 
in both commercial and academic settings, for— 
(A) positions necessary for the collection 
and transplantation of stem cell therapeutics, in-
cluding bone marrow and cord blood; and 
(B) positions in the field of regenerative 
medicine using adult stem cells and related to 
product development; 
(2) the identification of gaps, if any, in the pro-
jected workforce capacity for— 
(A) 
positions 
described 
in 
paragraph 
(1)(A); and 
(B) the field of regenerative medicine using 
adult stem cells, including workforce gaps related 
to the development of new cellular therapies 
using adult stem cells;
† HR 4764 EAS 
(3) an overview of the availability of training 
programs related to the development, refinement, and 
utilization of adult stem cells, including training on 
good manufacturing practices for such activities, and 
the performance of such programs; and 
(4) recommendations, if any, for improving the 
workforce capacity related to— 
(A) the positions described in paragraph 
(1)(A); or 
(B) the field of regenerative medicine using 
adult stem cells. 
Attest: 
Secretary.